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Clinical practice guidelines 
Clinical practice guidelines are defined as “systematically developed statements to assist care providers and 
patient decisions about appropriate health care for specific clinical circumstances” [1]. Clinical guidelines are 
intended as neither cookbook nor textbook, but should be helpful in everyday clinical medical decision-making 
about appropriate and effective care. Therefore, clinical guidelines should be presented in formats easy to 
interpret. 
Aim and structure of this manual 
The principal aim of this manual is to provide stepwise advice to individual members of ESHRE guideline 
development groups (GDG).   
The manual is based on the ESHRE manual for guideline development 2014, and draws on the most up-to-date 
evidence on international guideline development methodology and resources available, including Grading of 
Recommendations Assessment, Development, and Evaluation (GRADE).   
In addition, the manual is based on internationally acceptable criteria of methodological quality, as articulated by 
the Appraisal of Guidelines for Research and Evaluation in Europe (AGREE) instrument [2,3]. All 23 items of the 
AGREE Reporting checklist were incorporated in the manual, and listed as tips at the end of each chapter. 
The structure of this manual follows guideline development from its proposal through to publication and beyond. 
This ESHRE manual is intended to be a “living” publication and it will be updated regularly based on new 
developments in guideline development and experiences in the guideline groups. Comments on either content 
or presentation are welcome and should be sent to guidelines@eshre.eu. At the time of change, GDG members 
will be notified. 
Previous versions 
• Manual for ESHRE guideline development v1. 2007 
• Manual for ESHRE guideline development v2. 2014 
Details on the update 2017 
As stated, the manual for ESHRE guideline development is a “living” document and guideline development 
methodologies have changed over time. Since the update of the manual in 2014, ESHRE has endorsed the GRADE 
methodology for guideline development [4]. As GRADE provides not only guidance for quality assessment and 
formulation of recommendations, but also for scoping and key question formulation, a full update of the manual 
was necessary. Furthermore, experience with guideline development has led to significant improvements that 
have increased the quality of the guidelines, with a reduced workload and time needed for development. 
Finally, repetitions of information were deleted from the manual and each of the 12 steps clarified, in an attempt 
to make this manual more user-friendly for GDG members.  
 
GRADE: Key Points 
• GRADE offers a transparent and structured process for developing and presenting summaries of evidence, including its 
quality, for systematic reviews and recommendations in health care. 
• GRADE provides guideline developers with a comprehensive and transparent framework for carrying out the steps 
involved in developing recommendations. 
• GRADE’s use is appropriate and helpful irrespective of the quality of the evidence: whether high or very low. 
• Although the GRADE system makes judgments about quality of evidence and strength of recommendations in a 




The main goal of ESHRE guideline development is the provision of clinical recommendations to improve the quality 
of health care delivery within the European field of human reproduction and embryology. (For more information 
on ESHRE visit www.eshre.eu). 
ESHRE guideline development methodology is similar to the methodology of other societies [5-7,4] and complies 
with the criteria used by the AGREE instrument for good quality guidelines [2,3]. Furthermore, all relevant items 
of the Guidelines International network (GIN) Guideline Development Checklist were included [8,9].    
ESHRE clinical guidelines contain recommendations on a particular clinical issue. These guidelines are based on 
the best available evidence (most relevant and highest level of evidence) and not on all evidence available. There 
is an explicit link between recommendations and their available evidence. Furthermore, scientific and clinical 
evidence take precedence over expert judgement. 
ESHRE Guidelines will not include a formal analysis of cost effectiveness of recommended as compared to 
established practice, as this is not the main aim, and is sometimes impossible because of the obvious differences 
in current European economic and healthcare systems. The clinical and organizational impact of costs on 
recommendations will be considered in GDG meetings, and if relevant, described in the justification section. The 
economic feasibility of recommendations will not be covered.  
ESHRE guidelines can be adapted and translated by National Societies ensuring more efficient use of resources 
and improvement of patient outcomes throughout Europe. ESHRE guidelines should therefore be flexible and 
adaptable such that individual circumstances can be taken into consideration. ESHRE has established a policy for 
translation of its guidelines to ensure quality and validity of translated documents.  
 
Medico-legal implications of ESHRE guidelines 
Potential medico-legal implications of clinical guidelines have been of ongoing concern to medical practitioners 
[10]. However, clinical guidelines are intended as an aid to clinical judgement, not to replace it. The ultimate 
decision about a particular clinical procedure or treatment will always depend on each individual patient’s 
condition, circumstances and wishes, and the clinical judgement of the healthcare team as is represented within 
the disclaimer in the beginning of each guideline. Clinical guidelines are not intended to deprive clinicians of their 
medical freedom to treat, nor relieve them of their responsibility to make appropriate decisions based on their 
own knowledge and experience.  
To clarify the legal perspective all ESHRE guidelines carry the following statement in the disclaimer: The aim of 
clinical practice guidelines is to aid healthcare professionals in everyday clinical decision about appropriate and 
effective care of their patients. However, adherence to these clinical practice guidelines does not guarantee a 
successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override 
the healthcare professional's clinical judgment in diagnosis and treatment of particular patients. Ultimately, 
healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical 
judgment, knowledge and expertise, and taking into account the condition, circumstances, and wishes of the 




Guideline development in 12 steps 
Guideline development, implementation, and evaluation is no linear process, but a cycle of interdependent 
activities. Key steps within this process are: topic selection, synthesis of evidence, formulation of 
recommendations, consultation and review, dissemination and implementation, evaluation and updating. 
 





The time taken to develop an ESHRE guideline varies according to the scope of the topic, the volume of relevant 
literature, the amount of feedback received and the time needed to reach consensus about some topics. In 




In an effort to cut costs and time, it is strongly recommended to organize GDG meetings in conjunction with other 
meetings/congresses. The use of e-mails and teleconference for communication is also strongly encouraged to 
increase efficiency and avoid unnecessary meetings and travel. 
A fixed budget is set to cover the costs of necessary meetings of a GDG. These expenses cover meeting costs, 
including travel (economy class tickets), accommodation, food and meeting facilities. Costs are reimbursed upon 
request within four weeks, on presentation of original receipts, invoices, bills, tickets etc., together with a 






Summary of meetings and timelines  
* The guideline development should start as soon as a proposal is approved, but can be postponed due to other 
projects or workload.  
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❶ TOPIC SELECTION 
 
Selection procedure 
The Coordinators of all Special Interest Groups (SIGs) are regularly invited to propose new guideline topics. These 
proposals are made on an application form (Appendix A), and subjects chosen are within the field of reproductive 
medicine and embryology with the aim of assisting physicians and laboratory staff in diagnosis and/or clinical 
management. 
Individual ESHRE members wanting to present a guideline topic are encouraged to contact the relevant SIG 
coordinator, who will be responsible for submitting the application form.  
ESHRE uses a 2-step selection procedure to decide which proposals for guideline development will be accepted. 
In a first step, all proposals will be checked by the ESHRE research specialist and, if relevant, a representative of 
the SIG SQART based on the following criteria: 
• Is the proposal complete? 
• Is the proposal clear and well organized? 
• Are the details in the proposal correct? 
• Is the topic appropriate for an evidence-based “Clinical” guideline? 
The research specialist will also add information on existing guidelines, and overlap with other ESHRE guidelines. 
To check the presence of existing guidelines the following websites will be screened: Guidelines International 
Network (www.g-i-n.net), National Guideline Clearinghouse (www.guideline.gov), American Society for 
Reproductive Medicine (www.asrm.org), the National Institute for Clinical Excellence (www.nice.org.uk) and the 
Royal College of Obstetricians and Gynaecologists (www.rcog.org.uk). All guidelines found must be evaluated by 
using the AGREE checklist. Adaptation of existing guidelines (rather than developing new guidelines) can be 
considered; methodologies for adaptation are available [11,12]. The Cochrane Library should be consulted to 
estimate the available existing evidence. 
If necessary, additional information is requested from the applicant to complete the proposal before submission 
to the ESHRE executive committee. 
In a second step the ESHRE executive committee evaluates the application for guideline development and decides 
whether the proposal is acceptable for ESHRE guideline development. The ESHRE executive committee may 
suggest revisions to the application. If not acceptable, the applicant will be informed of the reason. The decision 
of the executive committee and any comments, will be communicated to the applicant by the research specialist. 
Appropriate topic selection is important to ensure that an ESHRE guideline is relevant and addresses priority issues 
for the improvement of European reproductive medicine. Within the selection procedure priority is given on 
topics with: 
• high volume 
• high costs 
• major patient impact (e.g. health burden or high risks) 
• high practice variation (within Europe) 
• high ethical/legal impact 
• high improvement potential. 
Application procedure 
The guideline application form (Form Ⓐ) can be downloaded from the ESHRE website. Completed application 
forms should be sent to the ESHRE research specialist (guidelines@eshre.eu). 








Available forms/checklists:  




❷ FORMING GUIDELINE DEVELOPMENT 
GROUP 
 
Convening an effective guideline development group (GDG) is a crucial stage in producing a guideline; the GDG 
agrees on the key questions, considers the evidence and has considerable influence on the final guideline 
recommendations [13]. Therefore, it is strongly recommended that representatives of all key groups and 
disciplines affected by a guideline topic participate. 
Recruitment procedure 
When a topic is accepted for guideline development, the applicant/responsible SIG coordinator is invited to 
propose GDG members. At the kick-off meeting, and based on the scope of the guideline, the SIG coordinator and 
GDG can decide on the need for additional members. Additional members can be selected, or an application 
process can be set up by the research specialist where ESHRE members are asked to apply for a position in the 
GDG. At the start of the guideline development, all GDG members, except for patient representatives and invited 
experts, should be a member of ESHRE.  
Once all members have agreed to participate, the GDG can become functional. 
Chair of the Guideline Development Group 
The chairperson of the GDG is either the applicant, the responsible SIG coordinator, or any GDG member with 
appropriate expertise, and team-working skills. A GDG chair is appointed for a period of four years and should be 
a respected content expert, experienced in group facilitation, maintaining constructive dynamics, identifying and 
resolving conflicts, remaining neutral and objective, and having methodological expertise. 
Composition guideline development group 
Diversity is an essential feature of a GDG and its exact composition should be tailored to the guideline topic (and 
scope) and reflect the range of stakeholders involved. A GDG should comprise at least: 
• content expert(s) 
• non-expert clinician(s) 
• a patient or their representatives 
• allied health care provider(s) and an 
• ESHRE research specialist. 
Industry representatives are excluded from membership. 
A maximum of 10 to 15 GDG members are recommended in addition to the chairperson. Simultaneous 
membership of more than one active GDG is generally not recommended. 
In composing a GDG, the following points should be considered: 
• balance in geographical location; representatives from all parts of Europe  
• balance in gender  
• balance in expertise (academic, non-academic, senior, junior, ..) 
Depending on the guideline topic, a representative from a related society might be considered for membership 
of the GDG. In the case of a joint guideline development with partner organizations, the Executive Committee 




Responsibilities of guideline development group members 
To ensure that the GDG functions effectively and achieves its aims, all GDG members should engage to the 
following responsibilities:  
• Attend all GDG meetings 1 
• Sign a statement of confidentiality at the start of the project 
• Declare of any conflict of interest (in case of changes, and at least annually) 
• Contribute to the formulation of clinical questions (PICO questions) 
• Assess and summarize papers for a specific section of the guideline 
• Write a summary of evidence and draft recommendations for a specific section of the guideline 
• Participate in discussion and decision making, with acceptance and tolerance of varying viewpoints 
• Approve of the final recommendations 
New members should usually not be added to the GDG once the development process has started. Additionally 
needed expertise or the replacement of a GDG member should be discussed within the GDG group. The research 
specialist should ensure that new GDG members have all information on the previous steps in the guideline 
development and receive training similar to the rest of the GDG. 
The GDG will be supported by an ESHRE research specialist who will be responsible for overall project 
management, and organizing the meetings in collaboration with the chair of the guideline group. In addition, the 
research specialist will provide specific training on the different steps in guideline development during the 
guideline meetings. The aim of such training is to increase and equalize the level of guideline development 
expertise within a GDG. Finally, the research specialist will perform the literature searches, and collect all input in 
one guideline document.  
Patient participation 
Patient involvement in guideline development is important to ensure reflection of their needs, concerns and 
preferences, as they may have different perspectives on healthcare processes, priorities, and outcomes from 
those of health care professionals. Ideally, patients are involved starting from the scoping process [14]. Patient 
needs and preferences should be for each guideline at least be considered with respect to: 
• information 
• communication 
• health care organization 
• financial constraints 
• shared decision making, and 
• self-management. 
For the identification of patients’ views other methodologies can also be applied, including literature search, 
patient (organization) consultation e.g. by (focus group) interviews, and/or guideline review by patients or their 
representatives. 
Handling Conflicts of Interest 
Because ESHRE aims to ensure objectivity and independence in its European guidelines, the guidelines are 
developed without external funding. All GDG chairpersons and members, have to provide disclosure statements 
of all potential conflicts of interest and confidentiality (see forms Ⓑ and Ⓒ). To insure objectivity of the guideline, 
group members with conflicts of interest in specific topics can be excluded from performing evidence selection 
on one or more key questions. In addition, it can be relevant to ask a second GDG member to check and evaluate 
a certain key question.  
The issue of conflicts of interest and how these are handled should be discussed within the guideline development 
group before the evidence is selected and evaluated. The strategy and all disclosed conflicts of interest will be 
mentioned in the appendix of the guideline. The disclosure form must be updated if any individual changes occur 
during the guideline development process and will be updated at least annually and at the end of the guideline 
development process. 
                                                                




GDG members need to make collective decisions throughout the entire development of a guideline. Such 
consensus includes generating key questions, agreeing the best evidence to answer them, and formulating 
recommendations. There are many different approaches to making group decisions and reaching consensus – but 
there is no blueprint about which approach should be used. Resources for consensus development methods can 
be found in the systematic review by Murphy and others [13]. The most commonly used consensus development 







 Decide on methods for recruitment and enrollment of member for the GDG.  
 Consider the optimum group size for the guideline development group, particularly the guideline panel 
(e.g. too small of a group may lack sufficient experience, content expertise and wide representation, too 
large of group may lack cohesiveness and effective group interaction). 
 Finalize the selection and formation process within 2 months.   
 Set expectations and awareness of the group process through an introduction, training, and support for 
the guideline development group members (e.g. setting ideal conditions for group discussion and 
decision-making).  
 Set a quorum for meetings (e.g. 75% of group must be present to formulate guideline recommendations), 
but expect that all group members attend all meetings as far as possible. 
 
 Document the guideline group member selection process and roles to ensure transparency.  
 Record the composition of the GDG (names, professions, represented organizations, geographical 
location) within the guideline. 
 Record competing interests of the GDG within the guideline, particularly where the conflicts bear on 
specific recommendations. 
 Record within the guideline that its development was without external funding. 
 
Available forms/checklists:  
Ⓑ Disclosure form   




❸ SCOPING THE GUIDELINE 
 
The aim of the scoping process is to define the overall objectives of the guideline (e.g. potential impact and 
benefits), the patients and target users to whom the guideline is meant to apply and its relation to other (ESHRE) 
documents. 
Scoping procedure 
In general a scoping procedure will start with a kick-off meeting of the GDG. A preliminary literature search, or a 
survey of target users and patients can be performed to provide input for the scope of the guideline.  
The scoping checklist (form Ⓓ) is completed to document the consensus of the GDG on what is within and outside 
the scope of the guideline.  
Alternatively, the scoping procedure can be completed by the SIG coordinator and the first members of the GDG 
(for instance at the kick-off meeting) and used as a basis to further complete the composition of the GDG. 
In any case, the scope should be accepted by the entire group before the GDG begins to formulate the key 









 Guideline scoping provides the opportunity for patient consultation. 
 Set timelines for the whole guideline development process. 
 Establish a method and criteria to generate and prioritize a candidate list of topics to be addressed within 
the guideline (e.g. where evidence is most confusing or controversial, where there is currently uncertainty 
or inconsistency in practice, questions about screening, diagnosis, and treatment, etc.). 
 Consult appropriate stakeholders to ensure all relevant topics for the guideline have been identified and 
will meet the needs of the target audience(s). 
 
 Record the overall objectives of the guideline, and the specific health benefits. 
 Describe the population to whom the guideline is meant to apply. 
 Record the target users of the guideline. 
 
Available forms/checklists:  




❹ FORMULATING KEY QUESTIONS 
 
Effective and efficient guideline development involves asking and answering key questions. Key questions should 
be clear, focused and closely define the boundaries of the topic. They are important both as the starting point for 
the subsequent systematic literature review and as a guide for the development of recommendations. 
Developing and selecting key questions 
The key questions are developed from the guideline’s scope. The scope is divided into different clinical stages 
(e.g. diagnosis, prognosis, treatment) and for each stage key questions are defined. It is generally not acceptable 
to define key questions on topics that have not been covered in the scope. Generally, a list of key questions is 
proposed by the chair or after consulting the GDG members, which are further defined and structured at the first 
GDG meeting.  
Around 15-20 questions would be a reasonable number of key questions for guidelines taking 18-24 months to 
develop, but this depends largely on the complexity of the topic and the questions. It may be necessary to divide 
a guideline topic requiring more questions into subtopics or more guidelines. 
During the final selection of key questions within a guideline the overall guideline outline should be kept in mind; 
each step of a clinical scenario needs to be addressed in a logical sequence. For example: diagnostics, treatment 
options, monitoring options, potential benefits/risks, outcome, prevention, information provision. The GDG 
selects the definitive key questions by consensus. 
A significant proportion of the key questions will focus on interventions: these questions should be formulated in 
a structured format, based on the defined PICO components (see below):  
Should [intervention] vs. [comparison] be used for [health problem]/[population]? 
For intervention questions, PICO components should be defined, a formal evidence synthesis should be carried 
out, and GRADE evidence profiles should be developed.  
A similar approach is suggested for questions on diagnosis, although it is not yet relevant to create GRADE 
evidence profiles for diagnostic questions. The proposed structured question is:  
Should [intervention] vs. [comparison] be used to diagnose [target condition] in [health 
problem and/or population]? 
In addition to interventions and diagnosis, other types of questions may arise. Some of these questions will fit the 
PICO format (although some components may be non-applicable), and a systematic assessment of the available 
evidence can be relevant, and recommendations can be formulated. For other questions, a formal systematic 
assessment of evidence synthesis is often irrelevant. These questions are often answered in a narrative format 
and conclusions or good practice points, rather than recommendations, are formulated by the GDG. When 
defining these questions, the GDG should define whether a systematic or narrative review is relevant. Examples 
of questions, and how they can be handled are:  
• What causes the problem?   AETIOLOGY, RISK FACTORS  PICO 
• What is the frequency of the problem?  FREQUENCY, PREVALENCE  PO 
• Who will get the problem?   PROGNOSIS, PREDICTION  PICO 
• What is the definition?   DEFINITION   (narrative)  
• What is the clinical presentation?  DEFINITION   (narrative) 




Defining key questions as PICO questions 
The PICO framework is a well-accepted methodology for framing clinical questions [15]. This framework divides 
each question into four components (see also template for PICO questions Ⓔ): Patients/population, 
Interventions, Comparisons and Outcomes 
Table 4.1 Definition of PICO components and factors to consider [16,4] 2 
   Factors to consider when developing criteria 
P Patient Population 
the patients or 
population to whom the 
recommendations are 
meant to apply 
• How is the disease/condition defined? 
• What are the most important characteristics that describe the 
people? 
• Are there any relevant demographic factors (e.g. age, sex, 
ethnicity)? 
• What is the setting (e.g. hospital, community)? 
• Who should make the diagnosis? 
• Are there any other types of people who should be excluded from 
the review (because they are likely to react to the intervention in 
a different way)? 
• How will studies involving only a subset of relevant participants be 
handled? 




diagnostic, or other 
intervention under 
investigation (e.g. the 
experimental 
intervention, or in 
observational studies 
the exposure factor) 
• What are the experimental and control (comparator) 
interventions of interest? 
• Does the intervention have variations (e.g. dosage/intensity, 
mode of delivery, personnel who deliver it, frequency of 
delivery, duration of delivery, timing of delivery)? 
• Are all variations to be included (for example is there a critical 
dose below which the intervention may not be clinically 
appropriate)? 
• How will trials including only part of the intervention be 
handled? 
• How will trials including the intervention of interest combined 
with another intervention (co-intervention) be handled? 
• Identify whether or not multiple (treatment) comparisons 




intervention in the 
control group  
O Outcome the outcome(s) of interest 
• Main outcomes, for inclusion in the 'Summary of findings' table, 
are those that are essential for decision-making, and emphasis 
should be on patient-important outcomes. 
• Primary outcomes are the two or three outcomes among the 
main outcomes that the review would be likely to be able to 
address if sufficient studies are identified, in order to reach a 
conclusion about the effects (beneficial and adverse) of the 
intervention(s). 
• Secondary outcomes include the remaining main outcomes 
(other than primary outcomes) plus additional outcomes useful 
for explaining effects. 
• Ensure that outcomes cover potential as well as actual adverse 
effects. 
• Consider outcomes relevant to all potential decision makers, 
including economic data. 
• Consider the type and timing of outcome measurements.  
• Include both desirable (e.g. benefits, less burden, savings) 
and undesirable effects (e.g. harm, burden, costs, and 
decrease in patient autonomy).  
• Do not ignore important outcomes for which evidence may 
be lacking. 
                                                                
2 Additions in Italic based on GIN-McMaster Guideline Development Checklist [9] 
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Defining the patient population and intervention for guideline question is challenging, and should take into 
account the underlying biology. Defining a broad patient population or intervention may be okay if across the 
range of patients and interventions it is plausible that the magnitude of effect on the key outcomes is more or 
less the same. If that is not the case the review will generate misleading estimates for at least some 
subpopulations of patients and interventions, and the questions should be defined more narrow or split up. Also, 
and different to a systematic review calculating relative risks, recommendations may differ across subgroups of 
patients at different baseline risk of an outcome, despite there being a single relative risk that applies to all of 
them. Thus, guideline panels must often define separate questions (and produce separate evidence summaries) 
for high- and low-risk patients, and patients in whom quality of evidence differs.  
Another challenge is defining the comparators. Mostly, guideline groups will be strict in defining the intervention, 
but will define the comparator as “all other interventions”. Clarity in choice of the comparator makes for 
interpretable guidelines, and lack of clarity can cause confusion. 
In order to make sensible recommendations all relevant outcomes that are important or critical to patients for 
decision making must be considered and included. Recommendations cannot be made on the basis of information 
about single outcomes and decision-making always involves a balance between health benefits and harms. GDGs 
must base the choice of outcomes on what is important, not on what outcomes are measured and for which 
evidence is available. If evidence is lacking for an important outcome, this should be acknowledged, rather than 
ignoring the outcome. Most systematic reviews do not summarize the evidence for all important outcomes, and 
evidence from other sources should be included.  
In GRADE, outcomes should be classified on importance for decision-making in 3 categories; critical, important 
but not critical, and of limited importance. Ranking outcomes by their relative importance can help to focus 
attention on those outcomes that are considered most important, and help to resolve or clarify disagreements. 
Practically, to generate a list of relevant outcomes, one can use the following type of scales [4]: 
Rating scale: 
1 2 3 4 5 6 7 8 9 
of least 
importance 
       of most 
importance 
of limited importance 
for making a decision 
important, but not critical 
Critical 
for making a decision 
not included in evidence profile included in evidence profile included in evidence profile 
 
It is important to realize that the importance of outcomes is likely to vary within and across cultures or when 
considered from the perspective of the target population (e.g. patients or the public), clinicians or policy-makers. 
The perspective would generally be that of the patient, and a literature search can be conducted on patients’ 
values and preferences about the intervention in question in order to inform the rating of the importance of 
outcomes. Reviewing the evidence may provide the panel with insight about the variability in patients’ values, the 
patient experience of burden or side effects, and the weighing of desirable versus undesirable outcomes. 
However, often such evidence is not available and panel members should use their prior experiences with the 
target population to assume the relevant values and preferences. 
Modifications to the key questions 
In general, after consensus by the GDG, the key questions are final and modifications should be minimized. 
However, once the evidence has been searched, the key questions may need refining. In any case, the entire GDG 
should be informed of and agree with any changes to the key questions.  
Changes to the key questions could include:  
• Reassessment of the importance of the outcomes 
• Addition of an outcome: for instance the importance of an outcome (e.g. a serious adverse effect) may 
only become known after the evidence synthesis 
• Addition of an intervention that is relevant for the flow and consistence of the guideline 
• Specific search on an important subgroup, not defined as such in the PICO questions 
• Merging of key questions based on significant overlap of the evidence synthesis.  
As changes to the key questions imply additional work for the research specialist and the GDG members, these 








 Generate and document the key questions (e.g. clinical, health, policy) to be answered in the guideline 
using a standard format (e.g. PICO) and determine the criteria by which the questions generated will be 
prioritized if it is not feasible to answer all questions (e.g. survey guideline panel members, survey 
stakeholders). 
 Select no more than 15-20 key questions. 
 Define key questions in such a way that answering the question gives the opportunity to make a 
recommendation. 
 Think of formulating key questions in addition to health benefits - and on side effects and risks.  
 
 List all key questions in the guideline, at the start of each guideline section. 
 
Available forms/checklists:  
Ⓔ Template PICO Question 
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❺ SEARCHING EVIDENCE 
The identification and selection of evidence is an essential step towards answering the key questions. Secondly, 
in order to perform an evidence search the key questions should be translated into key words or search terms. 
The evidence search itself should be gathered in a systematic process to avoid or minimize bias. Finally, from the 
identified literature the relevant evidence should be selected for summary and evaluation. 
Literature search 
According to the Institute of Medicine, literature searching is the key step in developing valid guidelines, because 
incomplete or biased literature evaluation can lead to inappropriate recommendations. The search for relevant 
research should be comprehensive, based on explicit criteria, and the validity of the results should be judged in a 
rigorous and reproducible fashion [17]. 
ESHRE applies a stepwise methodology, common to guideline development, focusing on the best available 
evidence to address each key question [5]. A set of standard search filters is used for identification in the following 
order: 
• Systematic reviews/meta-analyses 
• Randomized controlled trials 
• Non-randomized studies / observational studies 
• Case reports/opinion documents. 
The literature search will be performed in this stepwise approach, but all studies will be available for selection. 
Where adequate published systematic reviews exist, it may be appropriate to select the review and additional 
studies from the time period since the review was conducted. If no systematic review exists, the next type of 
studies to be assessed are RCTs (at least for intervention questions), followed by non-randomized and 





The GDG should establish in advance a set of basic selection criteria (e.g. duration of a follow-up period, the 
primary outcome measure, age limits). The process for evidence identification should also be repeatable and 
transparent. The search strategy, including search terms, should therefore be documented and stored. This also 
simplifies running the search strategies to check the validity of a guideline. 
The ESHRE research specialist will conduct the literature searches, based on a list of search terms for each of the 
PICO questions defined by the GDG members. Literature searching includes at least MEDLINE/PubMed and the 
Cochrane Library, but additional sources can be covered (e.g. NHS Economic Evaluations Database (NEED), 
PsycInfo and Embase) specific to the topic under review. 
The searches are limited to: 
• peer reviewed published literature  
o the use of abstracts should be avoided except in very rare instances (and always combined with 
a search for the full paper) 
o unpublished clinical trials should be avoided to support any recommendation. 
• English language 
• human subjects 
• defined time frame; searches in a guideline update are limited to the period following the last publication 
of the guideline; if a suitable systematic review is identified, an update search is limited to the time period 
following the reported search cut-off date. 
Although the research specialist performs a preliminary level of selection based on title and abstract, the clinical 
expertise of GDG members is necessary to carry out the definitive selection of the search output.   
Different questions may be best answered by different databases, or may rely on different levels of evidence. 
Following evaluation of the first search results the key questions may be redefined and subsequent searches 
focused on the most appropriate sources and study types. As a result, the assembly of evidence is a stepwise and 
iterative process.  
Selection of evidence 
Papers are initially pre-selected according to title and abstract by the ESHRE research specialist and the final 
selection is made by the GDG member. 
First, the titles of the retrieved citations are scanned and those that fall outside the topic of the guideline are 
eliminated. Next, a quick check of the remaining abstracts identifies further papers not relevant to the key 
questions, and these are also excluded. The remaining abstracts are investigated if they fulfil the selection criteria 
agreed by the GDG. If no or incomplete information is available in the abstract, the reference is selected and in 
the next step, the full text is assessed for relevance and quality to ensure its validity and applicability. The study 
selection process is clearly documented and details the applied inclusion criteria.  
Role of qualitative research 
At present there is no established mechanism for incorporating qualitative studies in evidence based guideline 
development. Nevertheless, the use of qualitative studies can help identify issues of concern to patients. A 
qualitative approach to complement trial data in the collection of information on patient preferences and the 
values placed on outcomes would perhaps help bridge the gap between scientific evidence and clinical practice. 
In case qualitative studies are used to support recommendations, an appropriate quality assessment checklist 
should be used to validate the quality of the studies. 
Narrative or descriptive review are generally not selected during evidence synthesis, but they may be helpful as 
background information. These papers represent an interpretation of evidence in the context of experts' 
experiences and knowledge. Expert opinion is not evidence per se and should not be used as evidence; rather, 
experience or observations that support expert opinions should be described, identified and, if possible, appraised 





   
 
Tips 
 Follow systematic review methods (either full systematic reviews or rapid systematic reviews depending 
on the topic and organization’s framework) or provide a rationale for why this is not done. 
 Develop a protocol for locating, selecting, and synthesizing the evidence (e.g. conduct a search for 
existing systematic reviews, new systematic review and grey literature search) and determine the types 
of evidence to include (e.g. databases searched, types of studies, inclusion and exclusion criteria, 
searching for specific studies on adverse effects or deciding to abstract information on adverse effects 
from studies on benefit). 
 Found evidence gaps can be used for future research goals. 
 
 Document and store the search strategies used. 
 Record how patients’ perspectives are included within the evidence search. 
23 
 
❻ EVIDENCE SYNTHESIS 
Studies identified during the stepwise literature search should be reviewed to identify the most appropriate data 
for answering the key questions and ensure that recommendations are based on the best available evidence. This 
process should be explicit and transparent and should be carried out through a systematic review process. This 
involves selecting relevant studies (step 6), assessing relevance and quality, summarizing the results, and grading 
the evidence. 
Relevance and Quality check 
Relevance and quality assessment (template Ⓕ) of the selected evidence is necessary to ensure that 
recommendations are based on the highest quality evidence available. Quality assessment is performed on each 
individual study. However, if the study is a meta-analysis or systematic review quality assessment should be 
performed on the meta-analysis or review itself and not on the studies included. Depending on the type of study, 
different checklist should be used (checklists Ⓖ). For systematic reviews and meta-analysis, the AMSTAR quality 
assessment checklist is recommended. 
A study should be rejected if its quality is assessed as low. If no better evidence can be found, the study might be 
considered as low level evidence, comparable with expert opinions. 
In addition to the inherent quality of a paper, the applicability of findings (relevance) should also be assessed.  
Applicability or relevance is related to the definition of the components (PICO) of the formulated key questions. 
Comparison of the available articles with the defined PICO components guides the selection of papers with the 
relevant evidence. 
The validity of a study is the extent to which its design and conduct are likely to prevent systematic errors, or bias. 
There are four potential sources of systematic bias in healthcare trials: 
• Selection bias – randomization (Patients/population) 
• Performance bias – blinding (Intervention) 
• Attrition bias – handling participant loss (Comparison) and 
• Detection bias – outcome assessment (Outcome). 
One of the most important factors leading to bias and distorted treatment comparisons is patient assembly 
(selection bias). An appropriate method for preventing foreknowledge of treatment assignment is crucial for any 
study. True randomization is administered by someone who is not responsible for the recruitment of study 
subjects. Thus, studies are for the selection bias judged on the quality of the used allocation concealment 
methodology. 
Performance bias refers to systematic differences in the provision of care to the participants in the intervention 
and control group. Those providing and receiving care can be ’blinded’ to protect against unintended differences 
in care. 
Attrition bias, also known as exclusion bias, alludes to systematic differences in the approach to handling the loss 
of participants (e.g. withdrawals, dropouts, protocol deviations) in the two study groups. This may have great 
potential for biasing results. 
Detection bias is a systematic difference between two study groups in outcome assessment. Trials that blind those 
assessing outcomes are logically less likely to be biased than trials that do not. 
Risk of bias assessment categorizes studies as low, moderate or high-risk bias based on the 4 sources of potential 
bias. The assessment can then be used as a (1) a threshold for study inclusion (e.g. for studies judged at high risk 
of bias, this assessment constitutes grounds for study exclusion), or (2) a possible explanation for found 
differences in study results.  
Risk of bias assessment provides a structured evaluation of the possible sources of bias. However, it is important 
to go back to the question and assess how important the study flaws are in the interpretation of the overall results.  
The study selection procedure and results of the risk of bias assessment and relevance should be documented 
and will be published as an annex to the guideline. At this point the available evidence is ready for summary. 
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Evidence tables  
Evidence tables help to identify similarities and differences between studies. Data for inclusion within an evidence 
table should be extracted according to a standard template (checklists Ⓖ). Here, key characteristics of the study 
population (e.g. sample size, age), intervention (e.g. follow-up period, kind of intervention), comparison (e.g. IUI 
versus timed intercourse) and outcome measures (e.g. effect size) are important. The evidence table was updated 
to the recommendations of the evidence table working group of the Guidelines International Network 
(http://www.g-i-n.net/). The completed evidence tables will be published as an appendix to the guideline 
(Template evidence table Ⓗ).  
GRADE Evidence profiles and Summary of Findings Tables 
A GRADE evidence profile allows presentation of key information about all relevant outcomes for a given health 
care question. It presents information about the body of evidence (e.g. number of studies), the judgments about 
the underlying quality of evidence, key statistical results, and the quality of evidence rating for each outcome.  
A GRADE evidence profile is particularly useful for presentation of evidence supporting a recommendation in 
clinical practice guidelines. It includes:  
• A list of outcomes (those considered critical and important; classification of the importance can be 
added) 
• The number of studies and study design(s) 
• Judgements about each of the quality of evidence factors assessed; risk of bias, inconsistency, 
indirectness, imprecision, other considerations (including publication bias and factors that increase the 
quality of evidence) 
• The assumed risk; a measure of the typical burden of the outcomes, i.e. illustrative risk or also called 
baseline risk, baseline score, or control group risk 
• The corresponding risk; a measure of the burden of the outcomes after the intervention is applied, i.e. 
the risk of an outcome in treated/exposed people based on the relative magnitude of an effect and 
assumed (baseline) risk 
• The relative effect; for dichotomous outcomes the table will usually provide risk ratio, odds ratio, or 
hazard ratio 
• The absolute effect; for dichotomous outcomes the number of fewer or more events in treated/exposed 
group as compared to the control group 
• Rating of the overall quality of evidence for each outcome (which may vary by outcome) 
• Footnotes, if needed, to provide explanations about information in the table such as elaboration on 
judgements about the quality of evidence 
GRADE evidence profiles are used for discussion of recommendations during guideline meetings. Summary of 
findings tables provide similar information in a more accessible format. Where relevant, and at least for all 
interventions questions with more than 1 RCT available, summary of findings tables will be added in the guideline 
(either in the body text, or as an annex). The corresponding GRADE evidence profiles will be used for discussion, 
and are available upon request. Any studies summarized in GRADE evidence profiles should not be necessarily 
included in the evidence table.  
Quality of evidence for each outcome 
The quality of evidence reflects the extent to which our confidence in an estimate of the effect is adequate to 
support a particular recommendation. It gives the reader a quick impression of the quality of the supporting 
evidence, which is not necessarily related to the importance of the recommendation.  
Guideline panels must make judgments about the quality of evidence relative to the specific context for which 
they are using the evidence. 
The GRADE approach involves separate grading of quality of evidence for each patient-important outcome (across 
studies) followed by determining an overall quality of evidence across outcomes. Although the quality of evidence 
represents a continuum, the GRADE approach results in an assessment of the quality of a body of evidence in one 




Table 6.1: Quality of Evidence Grades [18] 
Grade Definition 
High 
(⊕⊕⊕⊕) We are very confident that the true effect lies close to that of the estimate of the effect. 
Moderate 
 (⊕⊕⊕⊝) 
We are moderately confident in the effect estimate: The true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is substantially different 
Low 
(⊕⊕⊝⊝) 
Our confidence in the effect estimate is limited: The true effect may be substantially different 
from the estimate of the effect. 
Very Low 
(⊕⊝⊝⊝) 
We have very little confidence in the effect estimate: The true effect is likely to be 
substantially different from the estimate of effect 
 
Factors determining the quality of evidence 
The GRADE approach to rating the quality of evidence begins with the study design (trials or observational studies) 
and then addresses five reasons to possibly rate down the quality of evidence and three to possibly rate up the 
quality [18].  
For intervention studies, randomized trials provide, in general, far stronger evidence than observational studies, 
and rigorous observational studies provide stronger evidence than uncontrolled case series. As such, RCTS 
without important limitations provide high quality evidence, while observational studies without special strengths 
or important limitations provide low quality evidence. 
In case of RCTs, 5 factors should be assessed to detect limitations and reduce the quality of the evidence (for a 
certain outcome). In observational studies, 3 factors should be assessed to detect strengths and increase the 
quality of the evidence (for a certain outcome). If one or more of these factors is met (and there is no reason for 
downgrading), it is possible to rate up the quality. 
Table 6.2: Factors for upgrading and downgrading quality of evidence [18] 




of the body of 
evidence 
Factors that may decrease 
the quality 
Factors that may increase the quality 








5. Publication bias 
1. Large effect 
2. Dose–response 
3. All plausible residual 
confounding would reduce the 
demonstrated effect or would 
suggest a spurious effect if no 
effect was observed 
High 
(⊕⊕⊕⊕) 











In the end, the overall quality of evidence for an intervention across outcomes, is the lowest quality of evidence 
for the critical outcomes, as the overall confidence in effect estimates cannot be higher than the lowest 
confidence in effect estimates for any outcome that is critical for a decision.  
Non-randomized experimental trials (quasi-RCT) without important limitations also provide high quality evidence, 
but will automatically be downgraded for limitations in design (risk of bias) – such as lack of concealment of 
allocation and tie with a provider (e.g. chart number). 
Although the GRADE approach focusses on RCTS, large observational studies, specifically multivariate regression 
analyses, can provide moderate quality evidence, and can answer questions that are impossible to be answered 
by RCTs. Quality assessment is essential and should focus on whether confounding factors are accounted for and 
data screened is sufficiently large.  
Case series and case reports are observational studies that investigate only patients exposed to the intervention. 







 Document and publish the search and selection of evidence, judging eligibility, range of evidence 
included, and search strategies used to ensure the methods are explicit and transparent. 
 Summarize the evidence using a concise summary (e.g. evidence table, evidence profile or summary of 
findings table) of the best available evidence for each important outcome, including diagnostic test 
accuracy, anticipated benefits, harms, resources (costs), the quality of evidence rating, and a summary 
of the relative and absolute results/estimate of effect for each outcome. 
 Assess the quality of evidence for each important outcome. 
 Assess and report the overall quality of evidence (e.g. lowest quality of evidence from outcomes rated as 
most important or critical, or highest quality of evidence when all outcomes point in the same direction). 
 Document the judgements made in appraising the quality of evidence to ensure they are transparent and 
explicit. 
 Record the set of evidence selection criteria. 
 Record the strengths and limitations of the evidence. 
 
Available forms/checklists:  
Ⓕ Template Relevance and Quality check 
Ⓖ Quality assessment checklists 
Ⓗ Template evidence table 
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Factors for downgrading the quality of evidence  
1. Risk of bias 
The risk of bias of the included studies should be assessed in relation to the effect on the outcome [19]. In assessing 
the studies, the weight of the studies in the meta-analysis should be considered as small studies with high risk of 
bias may not necessarily impact on the estimate of effect if combined with a very large study at low risk of bias.  
Guidance to assess risk of bias and corresponding downgrading for limitations in study design: 
Risk of 
Bias Across studies Interpretation Considerations GRADE 
Low risk of 
bias 
Most information 
is from studies at 





No apparent limitation 
No serious limitations, 
do not downgrade 
Unclear 
risk of bias 
Most information 
is from studies at 
low or unclear risk 
of bias 
Plausible bias 
that raises some 
doubt about the 
results 
Potential limitations are unlikely to lower 
confidence in the estimate of effect 
No serious limitations, 
do not downgrade 
Potential limitations are likely to lower 
confidence in the estimate of effect 
Serious limitations, 
downgrade 1 level 
High risk 
of bias 
The proportion of 
information from 
studies at high risk 
of bias is sufficient 








Crucial limitation for one criterion or some 
limitations for multiple criteria, sufficient 
to lower confidence in the estimate of 
effect 
Serious limitations, 
downgrade 1 level 
Crucial limitation for one or more criteria, 
sufficient to substantially lower 
confidence in the estimate of effect 
Serious limitations, 
downgrade 2 levels 
 
2. Inconsistency of results 
Estimates of treatment effect across studies can differ because of clinical heterogeneity (P, I, O: for instance larger 
effect with higher dose, or shorter time of follow-up), or methodological heterogeneity (differences in study 
design) [20]. 
In case of (unexplained) inconsistency, the quality can be downgraded, or subgroups can be presented.  
Inconsistency can be detected by assessing confidence intervals and direction of effect for the included studies in 
a forest plot, or by means of the outcome of statistical tests for heterogeneity (I² statistic; >60% = substantial, p-
value) 
3. Indirectness of evidence 
Downgrading for indirectness can be considered if the evidence from the studies is different from the PICO 
question [21]. Examples could be:  
• Indirect comparison between 2 interventions (A vs placebo and B vs placebo instead of drug A vs drug B)  
• Population : evidence in menopausal women instead of POI 
• Comparator 
• Outcomes: surrogate outcomes: bone density instead of fractures 
4. Imprecision 
In general, results are imprecise when studies include relatively few patients and few events and thus have a wide 
confidence interval (CI) around the estimate of the effect [22]. In this case, one may judge the quality of the 
evidence lower than it otherwise would be considered because of resulting uncertainty about the results.  
In general, downgrading for imprecision can be considered in cases of small sample size (optimal information size 




The optimal information size is the threshold of number of events that needs to be included. The criteria for the 
optimal information size can be estimate by plotting the background risk against a chosen relative risk reduction 









If the total number of patients included in a systematic review is less than the number of patients generated by a 
conventional sample size calculation for a single adequately powered trial, consider rating down for imprecision. 
Regarding the wide confidence intervals, downgrading is appropriate when the confidence interval crosses the 
clinical decision threshold between recommending and not recommending treatment. This clinical decision 
threshold should be set based on the intervention. For example, for an intervention with limited adverse events, 
inconvenience and cost, the threshold for an absolute reduction in pregnancy loss may be set at 0.5%, which 
means that even a small benefit of the intervention would lead to recommending it. Alternatively, for an 
intervention with significant toxicity, the clinical decision threshold could be set at at least 1%. A theoretical 
intervention with an absolute reduction of pregnancy loss of 1.3% (95% CI 0.6% to 2.0%), would be rated down for 
imprecision with the clinical decision threshold of 1%, but not with a threshold of 0.5%. 
5. Publication bias 
Publication bias is a systematic under-estimation or an over-estimation of the underlying beneficial or harmful 
effect due to the selective publication of studies [23]. Confidence in the combined estimates of effects from a 
systematic review can be reduced when publication bias is suspected, even when the included studies themselves 
have a low risk of bias. Funnel plots can be used as a means to detect publication bias.  
Factors for upgrading the quality of evidence [24] 
1. Large magnitude of effect 
When the body of evidence from observational studies yield large or very large estimates of the magnitude of an 
intervention effect, then we may be more confident about the results. Decisions to rate up quality of evidence 
because of large (RR>2 or RR<0.5) or very large effects (RR >5 or RR <0.2) should consider not only the point 
estimate but also the precision (width of the CI) around that effect. Furthermore, upgrading should only be 
considered in absence of any problems with risk of bias. 
2. Dose-response gradient 
The presence of a dose-response gradient has long been recognized as an important criterion for believing a cause-
effect relationship. The presence of a dose-response gradient may increase our confidence in the findings of 
observational studies and thereby increase the quality of evidence. 
3. Opposing plausible residual confounding 
The reason that in most instances we consider observational studies as providing only low-quality evidence is that 
unmeasured or unknown determinants of outcome unaccounted for in the adjusted analysis are likely to be 
distributed unequally between intervention and control groups, referred to as “residual confounding” or “residual 
biases.” On occasion, all plausible confounders (biases) from observational studies unaccounted for in the adjusted 
analysis (i.e. residual confounders) of a rigorous observational study would result in an underestimate of an 
apparent treatment effect. If, for instance, only sicker patients receive an experimental intervention or exposure, 
yet they still fare better, it is likely that the actual intervention or exposure effect is even larger than the data 
suggest. A parallel situation exists when observational studies have failed to demonstrate an association.  
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❼ DEVELOPING RECOMMENDATIONS 
Once the selection and summary of evidence is complete, the available evidence must be combined and 
condensed into recommendations.  
Recommendations are statements mostly proposing a course of action. An ESHRE guideline recommendation 
should be a stand-alone text written in a complete sentence.  
Based on the available evidence, each GDG member prepares specific recommendations and presents them to 
the other GDG members at the GDG meeting. In addition to the evidence summary, the full systematic review(s) 
and the original studies and other sources of evidence will be available for the entire GDG during the process and 
prior to the meetings to inform deliberations (through a collaborative website and/or via electronic 
communication).  
When the GDG has reached consensus on the recommendations, the draft version of the guideline can be written. 
Strong or weak recommendations 
The strength of a recommendation reflects the extent to which a guideline panel is confident that desirable effects 
of an intervention outweigh undesirable effects, or vice versa, across the range of patients for whom the 
recommendation is intended. 
According to GRADE, recommendations are classified as “strong” or “weak”. The strength of a recommendation 
may not be directly correlated with its priority for implementation [25]. 
When the GDG formulates a strong recommendation, they have to be certain about the various factors that 
influence the strength of a recommendation. The GDG also should have the relevant information at hand that 
supports a clear balance towards either the desirable effects of an intervention (to recommend an action) or 
undesirable effects (to recommend against an action). When the GDG is uncertain whether the balance is clear 
or when the relevant information about the various factors that influence the strength of a recommendation is 
not available, a guideline panel should be more cautious and in most instances it would opt to make a weak 
recommendation. Alternatively to weak recommendations, the terms conditional (depending on patient values, 
resources available or setting) or discretionary (based on opinion of patient or practitioner) can be used. 
Table 7.1: The implications of the two grades of strength of recommendations in the GRADE approach [25], 









Good practice points 
(GPP)** 
Patients Most people in your 
situation would want the 
recommended course of 
action and only a small 
proportion would not. 
The majority of people in your 
situation would want the 
recommended course of action, but 
many would not. 
The test or 
intervention should 
only be considered by 
patients and clinicians 
within the setting of a 
research trial for 
which appropriate 
approvals and safety 
precautions have been 
established 
Clinicians, patients and 
policy makers are 
informed of the advice of 
the GDG regarding a 
certain recommendation. 
Clinicians 
Most patients should receive 
the recommended course of 
action. 
Recognize that different choices will 
be appropriate for different patients 
and that you must make greater 
effort with helping each patient to 
arrive at a management decision 
consistent with his or her values and 
preferences. Decision aids and 




The recommendation can be 
adopted as a policy in most 
situations. 
Policy making will require substantial 
debate and involvement of many 
stakeholders. 
NA 
* Strong recommendations based on high quality evidence will apply to most patients for whom these recommendations are made, 
but they may not apply to all patients in all conditions; no recommendation can take into account all of the often-compelling unique 
features of individual patients and clinical circumstances. 
** A good practice point or GPP is written by the GDG to support the recommendations. Advice can for instance be provided on how 




Table 7.1 will be provided in the methodology section of the guidelines to provide clear direction on the 
implication of the strength of recommendation for clinicians, patients, policy makers, and any other target 
audience groups. 
 
The decision on a strong or a weak recommendation depends on 5 key factors [26,4]. Judgement on these factors 
will be documented in a framework and summarized (narratively), with information on the explicit link between 
the recommendation and evidence supporting the recommendation in a justification statement in the guideline.  
 
Table 7.2: Key factors for deciding on a strong or a weak recommendation [26,4]:  
Factors Comment 
Balance between desirable and undesirable outcomes 
(trade-offs) taking into account: 
- best estimates of the magnitude of effects on desirable and 
undesirable outcomes 
- importance of outcomes (estimated typical values and 
preferences) 
The larger the differences between the desirable 
and undesirable consequences, the more likely a 
strong recommendation is warranted. The 
smaller the net benefit and the lower certainty 
for that benefit, the more likely a weak 
recommendation is warranted. 
Confidence in the magnitude of estimates of effect of the 
interventions on important outcomes (overall quality of 
evidence for outcomes) 
The higher the quality of evidence, the more 
likely a strong recommendation is warranted. 
Confidence in values and preferences of patients and their 
variability 
The greater the variability in values and 
preferences, or uncertainty about typical values 
and preferences, the more likely a weak 
recommendation is warranted. 
Resource use The higher the costs of an intervention (the more 
resources consumed), the less likely a strong 
recommendation is warranted. 
Health system perspective, including  
- equity (what would be the impact on health inequities?),  
- acceptability (is the option acceptable to key 
stakeholders?)    
- feasibility (is the option feasible to implement?) 
A higher impact on equity, acceptability and 
feasibility makes a strong recommendation more 
likely. 
 
The methods in which the additional information is to be incorporated with the synthesized evidence is 
documented in the annex of the guideline to ensure transparency (e.g. formal consensus on patient values, 
consensus on equity issues, formal economic analysis, consideration of disaggregated resource use data in a 
qualitative manner). 
Regarding resource use, the guideline will not include a formal analysis of cost effectiveness of recommended 
practice versus current or established practice. The economic feasibility of recommendations will also not be 
covered. The clinical and organizational impact of recommendations on costs will be considered in the GDG 
meetings and, if relevant, described in the justification section of the guideline.  
Wording of recommendations 
ESHRE guideline recommendations could stand alone and contain enough detailed information to be 
understandable without references to supporting material. Recommendations are written in complete sentences 
and should answer the key questions. In addition, the wording must be: 
• unambiguous 
• clearly defined 
• actionable 
• easy to translate into clinical practice and 
• agreed by the complete GDG. 
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Indicate in the recommendation statements the population for which the recommendation is intended, the 
intervention being recommended, and the alternative approach(es) or intervention(s). A help to guarantee the 
formulation of such clear recommendations is the five ‘W’ rule: each recommendation should be a description 
about who does what for whom, when and in which way.  
 
Possible benefits and harms should be quantified as much as possible. Any exceptions to the recommendations 
should be listed whenever possible. 
Despite the lack of studies supporting this, a standardized wording is usually defined reflecting the strength of the 
recommendation. Standardized wording to use for recommendations provides structure for the GDG members 
and aids to ensure clarity and to maintain consistency throughout the guideline, avoiding wording that may be 
vague and nonspecific (see table 7.3).  




It is recommended*  
It is indicated 
Do* 
Weak recommendation 
It is probably recommended 
It is conditionally recommended* 
It is suggested* 
Clinicians might* 
Clinicians could consider 
Clinicians may/might consider 
Good practice point (GPP) The GDG recommends 
  * suggested by the GRADE working group 
Good practice points (GPPs) are not an alternative to evidence based recommendations; any evidence relating to 
a key question excludes the possibility of using a GPP to make a recommendation. GPPs might be used to 
emphasize the importance of patient participation in decision making about specific procedure, provide advice 
on the management of specific surgical procedures for which there is an evidence based recommendation, or 
advise caution where there is perceived risk of harm but no available direct evidence of such harms [5].  
If the GDG group feels strongly that they want to make a recommendation even though there is no significant 
evidence, this should be done as a weak recommendation rather than a GPP. For such recommendation, the 
evidence can consist of opinion (from outside the GDG) supporting the recommendation. If no such evidence 
exists, formal methods should be used to develop a consensus based recommendation which will be clearly 
identified as such within the guideline by a statement accompanying the recommendation. The methods used to 
reach consensus should be described in the methodology annex of the guideline.  
For newer diagnostic tests and interventions, the GDG is encouraged to clearly state whether the test/intervention 
is recommended in routine clinical practice or whether it can be used only in a research context. Further data 
could allow for a more comprehensive recommendation in the update of the guideline.  
For some tests and interventions, the GDG may decide not to make a recommendation at all.  
Research recommendations 
In discussing the available evidence and its shortcomings, the GDG may feel it is important to formulate 
recommendations for future research. Where possible, research recommendations should be specific, detailing 
the necessary type of studies (RCTs, large multicenter studies), but also the (specific) interventions, or patient 
subgroups where further research is needed. The aim of formulating research recommendations is to stimulate 
research with a direct impact on future clinical recommendations. For this aim, the GDG will also be asked to 







 If applicable, make provisions for formulating recommendations in situations where there is insufficient 
evidence or very low quality evidence (e.g. conditional recommendation with judgements laid out 
transparently, no recommendation if the guideline panel feels there is substantial risk that their decision 
may be wrong, recommend that the intervention be used in the context of research complemented by 
guidance for what are the best management options until further research becomes available). 
 Provide suggestions about whether the recommendations are appropriate to serve as performance 
measures/quality criteria (e.g. management options associated with strong recommendations based on 
high- or moderate-quality evidence are particularly good candidates for quality criteria, when a 
recommendation is weak, discussing with patients the relative merits of the alternative management 
strategies and appropriate documentation of this interaction may become a quality criterion). 
 
 Record or refer to the methodology used for recommendations’ formulation.  
- If no consensus is reached, describe the different views and options. 
- Record benefits and harms considerations. 
 Recommendations should be specific and unambiguous. 
 
Available forms/checklists:  





❽ WRITING THE GUIDELINE DRAFT 
Principles for writing 
Once key questions are answered and there is consensus about the guideline’s recommendations, the first draft 
version can be written. However, writing in committee requires prior agreement about the consistent use of 
terminology and writing style. ESHRE guidelines should be written in English and within a European scope. 
Furthermore, they should be comprehensive and flexible in order to allow adaptation to diverse settings and 
circumstances of clinical practice. 
The use of paragraphs and headings are recommended to facilitate readers’ navigation. Moreover, the use of 
tables, illustrations, figures and algorithms is encouraged. For guideline uniformity an ESHRE guideline is written 
according to an established structure. 
Guideline structure 
In general, an ESHRE guideline consists of 3 main parts; the introduction section, the key question-related part 
and the annexes. 
The introduction section is subdivided in the introduction to the guideline, and a clinical introduction. 
The introduction to the guideline includes the scope of the document based on the scoping checklist, information 
on target users, and details on how the guideline was developed (referring to an annex with the full methodology). 
If relevant, previous versions of the guideline are listed in this section. 
Depending on the topic of the guideline, the clinical introduction contains disease definition and terminology, 
prevalence, variation in practice, provision of suboptimal care, personal and societal costs. 
For the key question related part, the guideline development group determines a logical order for reporting the 
total collection of key questions with their recommendations. One such method is to follow the patients’ pathway, 
starting with the clinical evaluation (e.g. symptoms, risk factors) followed by the diagnostics, treatment options, 
follow-up, complications, information provision. Per key question, the following items are reported: 
• Key question  
• Evidence: a descriptive summary of the selected clinical evidence, with GRADE summary of findings 
tables (or a reference to the tables in annex). 
• Recommendations: one or more recommendations, in boxes with appropriate GRADE. 
• Justification: a summary of the relevant evidence (with most important limitations) and the 
considerations taken into account when determining the strength of the recommendations. In the case 
of non-consensus, practice statements about the different schools of thought should be recorded. 
Furthermore, the explanatory text gives room for considerations from ethical or legal perspectives. 
• References. 
If there are no recommendations for a certain section, a conclusion and justification can be written.  
The annexes contain: 
• List of abbreviations   
• Glossary   
• Summary of findings tables 
• Evidence tables  
• Details on the literature study: flowcharts, list of excluded studies   
• Guideline development group, with list of declared conflicts of interest   
• Research recommendations: describe gaps in scientific knowledge for future investigation   
• Methodology (Appendix 5), that describes the guideline development in detail: 
o Guideline development process in 12 steps, according to the manual: funding, tailored 
information on the scoping procedure, details on the literature searches (searched databases, 
timeframe, inclusion and exclusion criteria), methodology of writing recommendations, and the 
used guidelines’ manual version. 
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o Information on the quality of evidence, grades of recommendations and phrasing, i.e. basic 
information needed to understand and interpret the recommendations. 
o Strategy for review of the guideline draft: invited reviewers, review deadlines, processing of 
comments. 
o Guideline implementation strategy, tailored to the guideline. 
• Schedule for updating the guideline 
• List of reviewers in stakeholder consultation  
• Guideline versions and dissemination (e.g. existence of additional tools), if relevant. 
• Relationship with other existing guidelines or ESHRE documents, if relevant. 
• Key priorities for implementation, if relevant. 
A legal disclaimer is also added at the back of the cover of the guidelines.  
A summary of all recommendation (condensed version) will be published in one of the ESHRE journals. This version 







 Check if recommendations answer the key questions. 
 Use the AGREE Instrument (www.agreetrust.org) as a checklist.  
 Develop or adopt a standardized format for reporting the guideline, with specific structure, headings, and 
content. 
 Decide on the format(s) to be prepared for the guideline product(s) (e.g. full guideline, full guideline with 
technical report/systematic reviews, brief guideline for clinicians or policymakers, consumer version for 
patients) that will correspond to the dissemination plan. 
 Seek approval from all members of the guideline development group for the final document(s). 
 
 Link the recommendations explicitly to the supporting evidence. 
 Present the different management options clearly.  
 Present if appropriate expected exceptions for recommendation application.  
 Facilitate recommendation identification (e.g. bullets, numbering, boxes).  
 Discuss potential barriers in applying the recommendations. 




❾ STAKEHOLDER CONSULTATION 
The final stages of guideline development involve review by future users and approval by the parties involved. 
Within this phase the adequacy of the guideline document is evaluated, especially for its methodological quality, 
its clinical content and its applicability. 
Review procedure 
The review phase starts with a review of the guideline draft by several stakeholders. Their consultations concern 
in particular the guidelines’ comprehensiveness, the accuracy of evidence interpretation and the acceptance of 
recommendations. 
A sample of the target group, all members of the involved SIGs, patients’ representatives (lay reviewers), and 
representatives of national organizations are invited by email to review the draft. At the same time, the draft is 
web posted with an invitation to review for all ESHRE members. Interested reviewers must sign a statement of 
confidentiality and submit their review comments within six weeks. Following this procedure results in an addition 
to the reviewers' list which will be mentioned as an appendix to the guideline (Reviewer comments form Ⓙ). 
For adapted (parts of) clinical guidelines the ESHRE draft guideline should be also send for review to the original 
developers. 
The comments received from reviewers are tabulated and discussed in the stakeholder review report. The GDG 
will respond to each of the comments, but does not commit to altering the recommendations in all instances. If 
no change is made, the reasons for this will be recorded in the review report.  
Any alterations to the recommendations must be made with the agreement of the whole GDG and noted also 
noted in the review report. This reviewer comments processing report is published on the ESHRE website 
alongside the guideline.   
Additional options for stakeholder consultation 
An additional open meeting at the ESHRE annual meeting is also an option for review. This provides the 
opportunity to present preliminary conclusions and draft recommendations to a wider audience and to hear 
valuable suggestions for additional evidence or alternative evidence interpretation. Because participation in such 
a meeting generates a sense of ownership across geographical and disciplinary boundaries, the organization of 
such a meeting might accelerate the internal consensus process, the review procedure and final implementation. 
A draft guideline can also be pilot tested before a wider launch. This step can detect problems in formatting, 







 Use the reviewing and piloting phase as an opportunity to advertise the existence of a new guideline. 
 Set a policy and process for handling consumer and stakeholder feedback and dealing with different 
perspectives (e.g. ensure that diverse perspectives are taken into account in making decisions, provide 
transparent rationale for judgements made, provide an appeal process for stakeholders, publish 
consultation comments and the guideline development panel’s responses). 
 
 Record the stakeholder review reporting methodology, document the internal and external peer review 
process and, if applicable, publish consultation comments and the guideline development group’s 
responses. 
 Document the enrollment and selection of consumers and stakeholders for the guideline panel and the 
involvement and consultation with all other consumers and stakeholders to ensure explicit and 
transparent methods. 
 
Available forms/checklists:  






Final version & authorization 
After stakeholder consultation, the entire GDG should formally approve the final version of the guideline. 
After completion of all revisions, English language reviewers and proofreaders (and possibly lawyers) can be called 
upon when necessary.  







⓫ PUBLICATION, DISSEMINATION AND 
IMPLEMENTATION 
 
Dissemination of ESHRE guidelines is considered as a continuation of the work of the GDG and involves making 
guidelines accessible, advertising their availability, and distributing them widely. Guidelines are (most) effective if 
their dissemination and implementation are carefully considered and vigorously pursued. If not, the time, energy 
and costs devoted to their development are wasted and potential improvements in reproductive health care are 
passed. 
A range of dissemination strategies can be effective, for instance the: 
• use of short summaries 
• promotion of guideline’s development/existence 
• publication in professional journal(s) 
• publication on the internet and links on related websites 
Currently there is too little evidence to support decisions about which guideline dissemination strategy is efficient 
under which circumstances. In general, the use of multi-faceted dissemination strategies is recommended. 
The standard dissemination procedure for all ESHRE guidelines comprises publishing and announcement.  
Publications 
The document will be published at least in 2 formats:  
• Publication of the full guideline on the ESHRE website (www.eshre.eu/guidelines) 
• Publication of the summary guideline (including all recommendations) in one of the ESHRE journals. After 
publication, a link to the paper is added to the guideline page.  
Additional options 
Distribution of guidelines alone has been shown to be ineffective in achieving change in practice; guidelines are 
more likely to be effective if they are disseminated by a strategy based on barrier research, by an active 
educational intervention or by patient-specific reminders. However, the extent of potential clinical benefits and 
resources required to introduce guidelines - and the likely benefits and costs as a result of any provider’s behavior 
change - need to be considered carefully before developing additional tools. The efficiency of a dissemination 
strategy is best evaluated in the presence of different barriers and effect modifiers. 
Two more options are the development of algorithms and patient information: 
• An algorithm is a flow chart of the clinical decision pathway described in the guideline, in which process 
steps and decision points are linked by arrows. Whenever relevant and useful, flowcharts can be 
digitalized in decision-supports in a web-based or smartphone/tablet version. 
• Patient information summarizes the recommendations in the ESHRE guideline in everyday language. It 
aims to help patients understand the guideline’s recommendations and facilitates decision-making. 
Moreover, the patient information may be used by hospitals or patient organizations for developing their 
own information leaflets. Patient versions of guidelines will be developed in collaboration with the 
patient representative involved in the guideline and its accuracy and correctness will be checked by the 
chair, or a delegate guideline development group member. If possible, a review of the patient version 
will be organized by inviting all relevant patient organizations to send in comments. The final version will 
be distributed among all relevant patient organizations with an invitation to endorse it, and if necessary, 
translate it. The translated version should be checked by a guideline development group member of the 
specific country or the national representative of this country and should contain a disclaimer, provided 





All relevant ESHRE communication channels will be used to announce the release of a new guideline:  
• A newsflash on the ESHRE website’s homepage 
• A mailing to the members of the relevant SIGs, or all ESHRE members 
• An announcement in “Focus on Reproduction” 
• Promotion at the annual ESHRE meeting via different media. Optionally, participants will be informed 
about the development and release of new guidelines during a specific guideline session. 
• A mailing to all related National Societies are separately informed about the guideline release. They are 
asked to encourage local implementation by, for instance, translations or condensed versions, but they 
are also offered a website link to the original document.  
• All appropriate remaining stakeholders - for instance, European policy makers, patient societies and 
industry representatives - will be separately informed. 
Guideline translation and endorsement 
An important factor facilitating guideline implementation is endorsement by professional groups; endorsement 
indicates that the guideline has been examined closely by clinicians. Endorsement of ESHRE guidelines is always 
sought from relevant National Societies by informing their presidents. A list of the National Societies having 
officially endorsed a certain guideline is posted on the ESHRE website. 
ESHRE gives National Societies the optional right to translate, adapt and publish the translated guideline in their 
own national journals. All costs of carrying out these rights and of translating the guideline are for the National 
Societies.  
A policy for translation of ESHRE documents is available on the ESHRE website and consists of a straightforward 
4-step procedure of approval, translation, validation and publication. For translation of the summary guideline 
published in one of the ESHRE journals, permission of Oxford University Press (OUP) should be requested. 
For reasons of consistency only one translation of a certain ESHRE guideline in any given language is accepted by 
ESHRE. ESHRE reserves the exclusive right to publish the first edition of all ESHRE guidelines and post its translation 
on the ESHRE website. National Societies must secure copyright protection in their own country. 
Implementation and evaluation 
Guidelines do not implement themselves. Local ownership of the implementation process is crucial for changing 
practice. ESHRE is responsible for the development of European guidelines and their implementability, but not 
directly for their implementation into local practice. Nevertheless, the identification of barriers to guidelines’ 
acceptance is one of the first steps of an implementation process and has ideally been part of the guideline 
developmental phase. Instruments like The Guideline Implementability Appraisal instrument can be helpful for 
identifying obstacles to guideline implementation [27] (http://nutmeg.med.yale.edu/glia/doc/GLIA_v2.pdf). 
There are different types of barriers to guideline implementation: 
• internal to the guideline itself 
• factors related to the individual care providers (e.g. attitude and skills) 
• factors related to the (social) setting (e.g. patients’ and colleagues’ characteristics) 
• external factors related to the system (e.g. reimbursement). 
After the determination of factors affecting guideline adoption, the currently recommended approach is to plan 
a targeted intervention. However, there is no specific guidance available for translating identified barriers into 
tailor-made implementation interventions. Each implementation strategy is effective under certain 
circumstances, and a multifaceted approach is more likely to succeed than a single approach. Evaluation of such 
complex interventions is therefore important and mostly undertaken by investigators with research funding. 
Focusing on individual recommendations rather than on the guideline as a whole makes the implementation 
initiative more manageable. Criteria reflecting one or more of the six quality domains defined by the Institute of 
Medicine (safety, effectiveness, patient-centeredness, timely, efficiency and equitability) can help to prioritize 
guideline’s recommendations for this purpose. 
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At an appropriate time after dissemination and implementation an evaluation is necessary for insight into the 
impact of the guideline. Such an evaluation consists of several components, namely an assessment of: 
•  guideline dissemination 
•  change in practice performance 
•  change in health outcomes 
•  change in consumer’s knowledge and understanding 
•  economic consequences. 
Practice performance is usually measured by a clinical audit and indicators. The frequently used definition for an 
indicator is “a measurable element of practice performance for which there is evidence or consensus that it can 
be used to assess the quality, and hence change in the quality of care provided”. Based on the manual by the 
Agency for Healthcare Research and Quality (AHRQ) and additional literature on quality indicators in infertility, a 
set of quality indicators for each ESHRE guideline can be developed in a 3-step process: 
• The GDG members rank the recommendations on priority for implementation to obtain key 
recommendations. 
• The GDG members propose quality indicators for each key recommendation. 
• The GDG members determine the importance and the preparedness to measure for each quality 
indicator, in a stepwise process. 
For each step specific structured questionnaires should be developed. 
The resulting set of key quality indicators will be used to evaluate the quality of care and the impact of the 








 Develop or adapt tools, support, and derivative products to provide guidance on how the 
recommendations can be implemented into practice (e.g. mobile applications, integration with clinical 
decision support systems, make guideline adaptable as an educational resource for target audience for 
education outreach). 
 Make considerations for adaptation of the guideline and provide specific instructions for how target 
end users who would like to adapt the guidelines to other contexts can do so in a systematic and 
transparent way (e.g. modifying a recommendation based on local resources and baseline risk, 
implications that deviate from the judgements made by the guideline panel). 
 Conduct an internal evaluation (i.e. self-assessment) of the guideline development process, including 
the guideline panel meeting(s) held to formulate recommendations, by asking guideline group 
members for feedback. 
 Consider pilot testing the guideline with the target end users (e.g. with members of target audience and 
stakeholders who participated in the guideline development group).  
 Provide criteria and tools for target end users to monitor and audit the implementation and use of the 
guideline recommendations (e.g. identify outcomes that should change with implementation and 
suggest methods for measuring the outcomes). 
 Provide support and tools for prospective evaluation of the guideline to determine its effectiveness after 
implementation (e.g. using randomized evaluations where possible, using before-after evaluations 
cautiously due to uncertainties regarding the effects of implementation). 
 Consider the potential involvement of the guideline development group in prospective evaluation(s) of 
the guideline (e.g. partnering with organizations that implement the guideline to plan evaluation studies). 
 Plan to collect feedback and evaluations from users to identify how to improve the intrinsic 
implementability of the recommendations in subsequent versions of the guideline. 




⓬ UPDATING THE GUIDELINE 
Updating of guidelines is an essential part of guideline development, to ensure guidelines remain current and 
their quality is maintained [28]. New evidence is emerging constantly and recommendations may be 
compromised when they are no longer reflective of the current clinical evidence. An analysis of NICE guidelines 
showed that the median life span of the clinical guidelines was 60 months (95% CI 51 - 69) [29]. The authors also 
suggested a system of monitoring to detect guidelines that are quickly outdated. As new evidence is published at 
different rates in different fields, a full revision of guidelines after a fixed time period is not always appropriate. 
Recent publications on guideline updating propose systems of monitoring and assessment of the need for a 
review, before endeavoring on a formal update [28]. 
Guideline monitoring  
Guideline monitoring includes guideline assessment, streamlined systematic review and formal update. Guideline 
assessment aims to identify documents that are no longer applicable to current practice and documents with 
recommendations that may have been, have the potential to be, or are expected to be invalidated by new 
evidence. Guideline assessment can be performed by the document assessment questionnaire (6 questions, see 
tool Ⓚ).  
The application of the document assessment questionnaire classifies each guideline into one of the following four 
groups: (1) endorse, (2) defer, (3) review, or (4) archive the guideline. 
 
Only for guidelines categorized as review from the assessment are eligible for the next step. The research 
specialist performs a streamlined systematic review (without a full quality assessment) of new evidence using the 
original search strategy and study selection criteria and summarize the new evidence from studies and reviews.  
The clinical expert (or the entire GDG) reviews the new evidence to determine:  
(1) if it supports or contradicts current recommendations; 
(2) if the current recommendations cover all relevant subjects addressed by the new evidence, and  
(3) if strong evidence that may change the current recommendations is expected to be published in the 
near future.  
Based on the assessment for each PICO question, it is categorized as endorse, update or archive. Endorse means 
that the newly identified evidence supports the current recommendations with only minor changes or new 
qualifying statements; update means that the new evidence requires changes to the existing recommendations,; 
and archive means that the document cannot be endorsed or deferred, and a full update is not either feasible or 
desired. 
Complete or partial guideline update 
If a need for review is identified for one or more PICO questions (partial review), or the full guideline (complete 
review), approval for the update must be requested from the ESHRE Executive Committee by completing the 
application form, and a report of the assessment. A complete review, approved by the ESHRE Executive 
Committee will follow the usual process described in this manual. Updated guidelines are also subject to 
consultation and will follow the usual validation process. 
 
For all ESHRE guidelines, an annex will be added documenting the outcomes of the annual assessment and details 








 Decide who will be responsible for routinely monitoring the literature and assessing whether new 
significant evidence is available (e.g. consider involvement of experts not previously involved in the 
guideline development group to periodically review the guideline).  
 Make arrangements for guideline group membership and participation after completion of the guideline 
(e.g. rotating membership every 1-2 years, selection of a new group at time of updating, continuing 
participation by guideline panel chair).  
 Plan the logistics for updating the guideline in the future. 
 
 Refer to the procedure for guideline updating. 
 
Available forms/checklists:  
Ⓐ Application form 
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Ⓐ APPLICATION FORM 
GUIDELINE / CONSENSUS DOCUMENT  
APPLICANTS 
Contact person(s):  
 
ESHRE Special Interest Group(s) involved: 
 
TOPIC 
Proposed title:  
 
Guideline or Consensus document:  
 
Proposed (clinical) problem:  
 
The relevance of the proposed clinical problem (e.g. volume, costs and patient impact): 
 
Main outcome(s) to be addressed by the proposed guideline: 
 
Indication of actual practice variation: 
 
Expected benefit(s) from the proposed guideline development and implementation:  
 
Indication of the size and strength of the evidence for the proposed topic:  
 
Other comments: (in case of a consensus document, please clarify methodology, schedule and costs for the project) 
 
OTHER EXISTING GUIDELINES/CONSENSUS DOCUMENTS 
(to be completed by RS) 
Existing guidelines within the field of the proposed topic:  
 
Overlap with other ESHRE guidelines:  
 
The completed application form should be sent to guidelines@eshre.eu  
49 
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All ESHRE guideline development group members are expected to provide completed and signed disclosure 
statements about all financial, personal, or professional relationships with industry, individuals, or organizations 
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development process. 
 
ESHRE GUIDELINE:  
 
Contact information of the guideline development group member 
Name: ……………………………………………………………………………………… 
Institution, Address: ……………………………………………………………………………………… 
……………………………………………………………………………………… 
E-mail address: ……………………………………………………………………………………… 
 
Information on potential conflicts of interest from the last 3 years, or anticipated 
in the next 12 months 
 
○  I have no potential conflict of interest from the last 3 years to report 
○  I have the following potential conflict(s) of interest from the last 3 years to report: 
 ○ Research grant(s) from one or more companies, from ……………………………………………………………………… 
○ Consulting fee(s) for e.g. services on an advisory board or legal testimony, from…………………….………… 
○ Speaker’s fee(s) for instance as compensation for lecturing and travel, from …………………………………… 
○ Salary or position funding, from ………………………………………………………………………………………………..……… 
○ Ownership interest by stock (options) or partnership of a healthcare company, from ……………….……… 
○ Other (financial) benefit e.g. by institutional conflicts of interest in the topics or issues addressed in     
     the document: ……………………………………………………………………………………… 
 
Signature  
(or state your name): 
……………………………………………………………………………………… 





Ⓒ CONFIDENTIALITY FORM 
As a writer of an ESHRE guideline you have been or may be exposed to certain confidential and/or proprietary 
information, materials or data. It is important to the integrity of the writing process and final work that this 
information should be kept strictly confidential and not disclosed at any time under any circumstance. 
 
ESHRE GUIDELINE:  
 
Contact information of the guideline development group member 
Name: ……………………………………………………………………………………… 
Institution, Address: ……………………………………………………………………………………… 
……………………………………………………………………………………… 
E-mail address: ……………………………………………………………………………………… 
 
Statement of confidentiality 
 
I will not disclose any confidential and/or proprietary information, materials or data related to Guideline 
Development Group’s work to any third party, but keep this information strictly confidential. 
 
I will keep any confidential and/or proprietary information, materials or data in my possession in a safe and secure 
place to protect against inadvertent disclosure. 
 
I will not use any confidential information and/or proprietary information, materials or data for any purpose other 




(or state your name): 
……………………………………………………………………………………… 







Ⓓ SCOPING CHECKLIST 
 
1. What is/are the overall purpose(s) of the proposed guideline? 
Specify health intents (i.e., prevention, diagnosis, treatment, etc.) and expected benefits or outcomes. E.g. 
preventing thromboembolic complications of patients undergoing elective orthopedic surgery. 
 
2. What is the proposed target patient population? 
Specify subjects to whom those recommendations apply (i.e. patients, society, etc.). E.g. adults undergoing 
elective orthopedic surgery, all women 40 years of age or older, etc. 
  
3. What is the proposed health care setting? 
Specify level of health care (i.e. primary, secondary, etc.) where these recommendations are supposed to be 
implemented. 
 
4. Which interventions should be included in the guideline? 
Specify which preventive, therapeutic and diagnostic interventions will be covered and which will be not. 
 
5. Which outcome(s) should be addressed by the proposed guideline? 
Specify which outcome(s) would be preferred, which are commonly reported and which are preferred by patients. 
 
6. Who are the target users of the proposed guideline, and who are the key stakeholders? 
Specify all relevant professional groups, institutions, patients, public, etc. who are target users or beneficiaries of 
these guidelines and/or whose views should be sought. 
  
7. What prefers the proposed patient population?  
Is this already included? Which methodology/methodologies will be used to include patients’ preferences? 
  
8. What are key resources to consider? 
Specify resources needed for the implementation of guidelines (i.e. need for additional human resources, 
equipment, infrastructure, system changes, etc.) and potential barriers to implementation. 
 
9. What is the relation to other documents? 
List all existing documents/guidelines on the same or similar topic that are likely to be currently used in practice 







Ⓔ PICO CHECKLIST 
For each PICO questions, provide the following information: 
 





Outcomes:  critical  
 important  
 other  
  
Other databases to be 











                                                                
3 in addition to Medline/Pubmed and Cochrane Library 
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XX SR ○ YES 
○ NO 





If a paper is found to be not-relevant, or of low quality, the GDG member should list the exclusion criteria.  
(Remarks can be added in case of relevant good quality papers as well)  
Possible exclusion criteria (non-exhaustive list) 
• Not relevant:  
– Publication type : Case report - Expert opinion - Editorial 
– Relevant patients are not included, or only as subgroup 
– Relevant intervention is not included 
– Relevant outcomes are not assessed or inappropriately assessed  
– Study is included in meta-analysis / More recent meta-analysis available 
• Low Quality 
– Selection bias  
– Performance bias 
– Attrition bias 
– Detection bias 
– Other sources of bias 
• Study population: for instance too small 
• Methodology 





INSTRUCTIONS FOR THE GDG MEMBERS 
1. You will receive all full text papers and a relevance and quality check table with all references. 
For some full text papers we do not have access to the full text.  
2. Check whether the paper is relevant. If not, list an explanation/exclusion criterion 
3. If relevant, assess the quality of the paper (with the appropriate checklist for risk of bias assessment). 
List the most important criteria for your judgement on quality (especially in case of low quality) 




Ⓖ QUALITY ASSESSMENT CHECKLIST 
AMSTAR – a measurement tool to assess the methodological quality of systematic 
reviews [30]4. 
 
1. Was an 'a priori' design provided? 
The research question and inclusion criteria should be established before the conduct of the review. 
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published research 
objectives to score a “yes.” 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
2. Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus procedure for disagreements 
should be in place. 
Note: 2 people do study selection, 2 people do data extraction, consensus process or one person checks 
the other’s work. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
3. Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must include years and databases used 
(e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible 
the search strategy should be provided. All searches should be supplemented by consulting current 
contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by 
reviewing the references in the studies found. 
Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane register/Central 
counts as 2 sources; a grey literature search counts as supplementary). 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
The authors should state that they searched for reports regardless of their publication type. The authors 
should state whether or not they excluded any reports (from the systematic review), based on their 
publication status, language etc. 
Note: If review indicates that there was a search for “grey literature” or “unpublished literature,” 
indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries are all 
considered grey for this purpose. If searching a source that contains both grey and non-grey, must 
specify that they were searching for grey/unpublished lit. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the list but the link 
is dead, select “no.” 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
6. Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should be provided on the 
participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g., 
age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should 
be reported. 
Note: Acceptable if not in table format as long as they are described as above. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
                                                                
4 Additional notes (in italics) made by Michelle Weir, Julia Worswick, and Carolyn Wayne based on conversations with 
Bev Shea and/or Jeremy Grimshaw in June and October 2008 and July and September 2010. 
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7. Was the scientific quality of the included studies assessed and documented? 
‘A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose 
to include only randomized, double-blind, placebo controlled studies, or allocation concealment as 
inclusion criteria); for other types of studies alternative items will be relevant. 
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, sensitivity 
analysis, etc., or a description of quality items, with some kind of result for EACH study (“low” or “high” is 
fine, as long as it is clear which studies scored “low” and which scored “high”; a summary score/range 
for all studies is not acceptable).   
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
8. Was the scientific quality of the included studies used appropriately in formulating conclusions? 
The results of the methodological rigor and scientific quality should be considered in the analysis and the 
conclusions of the review, and explicitly stated in formulating recommendations. 
Note: Might say something such as “the results should be interpreted with caution due to poor quality of 
included studies.” Cannot score “yes” for this question if scored “no” for question 7. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
9. Were the methods used to combine the findings of studies appropriate? 
For the pooled results, a test should be done to ensure the studies were combinable, to assess their 
homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model 
should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e., 
is it sensible to combine?). 
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they cannot pool 
because of heterogeneity/variability between interventions. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
10. Was the likelihood of publication bias assessed? 
An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other 
available tests) and/or statistical tests (e.g., Egger regression test, Hedges-Olken). 
Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that publication bias 
could not be assessed because there were fewer than 10 included studies. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
11. Was the conflict of interest included? 
Potential sources of support should be clearly acknowledged in both the systematic review and the 
included studies. 
Note: To get a “yes,” must indicate source of funding or support for the systematic review AND for each 
of the included studies. 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
  
 







CHECKLIST: RANDOMIZED CONTROLLED TRIALS   
 
Selection bias (systematic differences between the comparison groups)  
An appropriate method of randomization was used to allocate participants to 




□ Can't answer 
□ Not applicable 
There was adequate concealment of allocation (such that investigators/participants 
cannot influence enrolment or treatment allocation)5 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was selection bias present? If 
so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Performance bias (systematic differences between groups in the care provided, apart 
from the intervention under investigation) 
 
The comparison groups received the same care apart from the intervention(s) studied □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Participants receiving care were kept 'blind' to treatment allocation □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Individuals administering care were kept 'blind' to treatment allocation6 □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was performance bias present? 
If so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Attrition bias (differences between the comparison groups with respect to loss of 
participants)7 
 
All groups were followed up for an equal length of time (or analysis was adjusted to 
allow for differences in length of follow-up) 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
                                                                
5 Lack of allocation concealment: Those enrolling patients are aware of the group (or period in a crossover trial) to which the next enrolled 
patient will be allocated (a major problem in “pseudo” or “quasi” randomized trials with allocation by day of week, birth date, chart number, 
etc.). 
6 Lack of blinding : Patient, caregivers, those recording outcomes, those adjudicating outcomes, or data analysts are aware of the arm to which 
patients are allocated (or the medication currently being received in a crossover trial) 
7 Incomplete accounting of patients and outcome events: Loss to follow-up and failure to adhere to the intention-to-treat principle in 
superiority trials; or in noninferiority trials, loss to follow-up, and failure to conduct both analyses considering only those who adhered to 
treatment, and all patients for whom outcome data are available. 
The significance of particular rates of loss to follow-up, however, varies widely and is dependent on the relation between loss to follow-up 
and number of events. The higher the proportion lost to follow-up in relation to intervention and control group event rates, and differences 
between intervention and control groups, the greater the threat of bias. 
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The groups were comparable for treatment completion. (How many participants did 
not complete treatment in each group?) 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The groups were comparable with respect to the availability of outcome data (For how 
many participants in each group were no outcome data available?)8 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was attrition bias present? If so, 
consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Detection bias (bias in how outcomes are ascertained, diagnosed or verified)   
The study had an appropriate length of follow-up □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The study used a precise definition of outcome □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
A valid and reliable method was used to determine the outcome □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Investigators were kept 'blind' to participants' exposure to the intervention and other 
important confounding and prognostic factors 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was detection bias present? If 
so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Overall quality of the RCTs   
Is the methodology used for the RCT   sufficiently robust to permit a valid conclusion? □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
What is your overall assessment of the methodological quality of this RCT 
 
□ HIGH QUALITY  
□ MODERATE QUALITY 
□ LOW QUALITY 
□ VERY LOW QUALITY 
 





                                                                
8 Incomplete or absent reporting of some outcomes and not others on the basis of the results. 
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CHECKLIST: COHORT STUDIES   
 
Selection bias (systematic differences between the comparison groups)  
The method of allocation to treatment groups was unrelated to potential confounding 
factors (that is, the reason for participant allocation to treatment groups is not expected 
to affect the outcome[s] under study) 9 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was selection bias present? If 
so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Performance bias (systematic differences between groups in the care provided, apart 
from the intervention under investigation) 
 
The comparison groups received the same care apart from the intervention(s) studied □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Participants receiving care were kept 'blind' to treatment allocation □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Individuals administering care were kept 'blind' to treatment allocation □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was performance bias present? 
If so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Attrition bias (differences between the comparison groups with respect to loss of 
participants)  
 
All groups were followed up for an equal length of time (or analysis was adjusted to 
allow for differences in length of follow-up) 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The groups were comparable for treatment completion. (How many participants did 
not complete treatment in each group?) 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The groups were comparable with respect to the availability of outcome data (For how 
many participants in each group were no outcome data available?) 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
                                                                
9 Failure to develop and apply appropriate eligibility criteria (inclusion of control population): Selection of exposed and unexposed in cohort 
studies from different populations 
10 Failure to adequately control confounding: Failure of accurate measurement of all known prognostic factors - Failure to match for 




Based on your answers to the above, in your opinion was attrition bias present? If so, 
consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Detection bias (bias in how outcomes are ascertained, diagnosed or verified)   
The study had an appropriate length of follow-up11 □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The study used a precise definition of outcome □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
A valid and reliable method was used to determine the outcome □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Investigators were kept 'blind' to participants' exposure to the intervention and other 
important confounding and prognostic factors 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Based on your answers to the above, in your opinion was detection bias present? If 
so, consider the likely direction of its effect? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Overall quality of the cohort studies   




□ Can't answer 
□ Not applicable 
What is your overall assessment of the methodological quality of this study 
 
□ HIGH QUALITY  
□ MODERATE QUALITY 
□ LOW QUALITY 
□ VERY LOW QUALITY 
 




                                                                
11 Incomplete or inadequately short follow-up: Especially within prospective cohort studies, both groups should be followed for the same 
amount of time. 
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CHECKLIST: CASE CONTROL STUDIES   
 
Selection bias (systematic differences between the comparison groups)  
The cases and controls are taken from comparable populations   □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The same exclusion criteria are used for cases and controls □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
The participation rate was similar between cases and controls, and participants and non-
participants are compared to establish their similarities and differences 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Cases are clearly defined and differentiated from controls □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Performance bias (systematic differences between groups in the care provided, apart 
from the intervention under investigation)  




□ Can't answer 
□ Not applicable 
Exposure status is measured in a standard, valid and reliable way □ Yes 
□ No 
□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 
Detection bias (bias in how outcomes are ascertained, diagnosed or verified)   
Have confidence intervals been provided □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Overall quality of case-control studies    




□ Can't answer 
□ Not applicable 
What is your overall assessment of the methodological quality of this study 
 
□ HIGH QUALITY  
□ MODERATE QUALITY 
□ LOW QUALITY 
□ VERY LOW QUALITY 
 
Note: the outcome of the quality assessment should be documented in the relevance and quality check document. 
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CHECKLIST: STUDIES OF DIAGNOSTIC ACCURACY   
Checklist based on QUADAS tool [31] 
  




□ Can't answer 
□ Not applicable 
Were selection criteria clearly described? □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Is the reference standard likely to classify the target condition correctly? □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Is the period between reference standard and index test short enough to be 
reasonably sure that the target condition did not change between the two tests?  
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Did the whole sample or a random selection of the sample receive verification using 
a reference standard of diagnosis? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Did patients receive the same reference standard regardless of the index test result?  □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Was the reference standard independent of the index test (i.e. the index test was not 
part of the reference standard)? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Was the execution of the index test described in sufficient detail to permit replication 
of the test? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 




□ Can't answer 
□ Not applicable 
Were the reference standard results interpreted without knowledge of the results of 
the index test? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Were the same clinical data available when test results were interpreted as would be 
available when the test is used in practice? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Were uninterpretable/intermediate test results reported? □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
Were withdrawals from the study explained? □ Yes 
□ No 
□ Can't answer 
□ Not applicable 
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Overall quality of the diagnostic studies  
 
Is the methodology used for the diagnostic cohort study sufficiently robust to states 
the conclusion is reliable? 
□ Yes 
□ No 
□ Can't answer 
□ Not applicable 
What is your overall assessment of the methodological quality of this study □ HIGH QUALITY  
□ MODERATE QUALITY 
□ LOW QUALITY 
□ VERY LOW QUALITY 
 




Ⓗ EVIDENCE TABLES  
Intervention studies 
 

















Harms  / 
adverse 
events 
Effect size Authors 
conclusion 
Comments 




REFERENCE (+PMID) author, journal, year, volume and pages + PMID  
Study type Meta-analysis/ systematic review (SR), randomized controlled trial (RCT), non-




characteristics + group 
comparability 
total number of patients, and the number of patients involved in each group  
Describe relevant baseline characteristics (age, disease status, inclusion / 
exclusion criteria,..), if stated per group and add comment for comparability of 
groups.  
Interventions (+comparison) 
Include Study duration /  follow-
up 
Specify the interventions per group (treatment/procedure (dose, regimen, 
length,..) / placebo/alternative treatment / expectant management) 
duration patients participate the study from inclusion to a specified end-point 
(e.g. implantation) or the end of data collection, mention per outcome if relevant 
Outcome measures 
(primary/secondary) 
Include Harms / adverse events 
All outcome measures (positive and negative): e.g. OHSS occurrence rate, 
implantation rate, pregnancy, quality of life, satisfaction,..  
Divide between primary (1) and secondary (2) outcomes when this is specified by 
the author 
Effect size  
(include Harms) 
Absolute risk reduction, relative risks, numbers needed to treat/harm, or odds 
ratios with confidence intervals; State clearly which outcome measure is used. 
Add p-values, if available. 
Define and describe observed harms per group as reported in the paper. Precise 
mean, percentages and p-values, if available 
Authors conclusion Report the Authors conclusion 
Comments Additional characteristics/interpretations or flaws of the study, additional 
calculations made by the reviewer (NNT, RR, OR, CI,..) 
If relevant, mention the source of funding, or any competing interests.  
If the paper is to be excluded, mention the exclusion criterion here.  
When no element can be added, include:  
“Not applicable (NA)” when an item is not to be informed, or  


































REFERENCE (+PMID) author, journal, year, volume and pages + PMID  
Study type Meta-analysis/ systematic review (SR), randomized controlled trial (RCT), non-




characteristics + group 
comparability 
total number of patients, and the number of patients involved in each group  
Describe relevant baseline characteristics (age, disease status, inclusion / 
exclusion criteria,..), if stated per group and add comment for comparability of 
groups.  
Setting:  Multicentre, countries, healthcare setting,. 
Diagnostic test evaluated 
Reference standard test Include: 
Time interval and treatment 
Describe the evaluated test (what, by whom and how, when,..), cut offs, blinding 
to clinical information and/or index test results 
Describe the evaluated test (what, by whom and how, when,..), cut offs, blinding 
to clinical information and/or index test results  
Specify the time interval and treatments administered between the tests (if any) 




Disease prevalence  
Accuracy: Give all available figures with confidence intervals (if available): 
Sensitivity  (Se),  Specificity  (Sp),  positive  predictive  value  (PPV),  negative 
predictive value (NPV), likelihood ratios (LR, LR-), area under the ROC curve 
Reproducibility: Give all available figures with confidence intervals (if available): 
- Quantitative  test  (number  of  repetitions,  extent  of  values,  
agreement, correlation) 
- Qualitative test (reliability, correlation coefficient,..) 
Authors conclusion Report the Authors conclusion 
Comments additional characteristics/interpretations or flaws of the study, additional 
calculations made by the reviewer 
If relevant, mention the source of funding, or any competing interests.  
If the paper is to be excluded, mention the exclusion criterion here.  
When no element can be added, include:  
“Not applicable (NA)” when an item is not to be informed, or  






INSTRUCTIONS FOR THE GDG MEMBERS 
5. You will receive all full text papers and an empty evidence table with all references. 
For some full text papers we do not have access to the full text.  
6. For some papers, you do not have to complete the evidence table:   
In the last column remarks have been added. 
- “GRADE evidence profile”: this meta-analysis or RCT will be added to a GRADE Profile. You can 
add your comments to the meta-analysis or RCT, but you do not need to complete all details. 
- “EXCLUDE”: Usually studies that are relevant but have been included in a meta-analysis. You 
can leave this blank. If at some point the meta-analysis is found to be of low quality, we may go 
back and complete the information in the evidence table.  
- Any other comment on the paper – you can decided whether or not to complete the evidence 
table 
7. Read the paper thoroughly 
- Complete the evidence table: fill in as much information as possible that is relevant for 
answering the PICO question. (see detailed instructions below for intervention and diagnostic 
studies) 
- Even though you have already judged the paper as “good quality” and “relevant”, you can 
exclude papers at this stage. If you would like to exclude a paper, you do not have to complete 
the evidence table, just add a remark in the last column: “excluded due to … ” 
- In the last column of the evidence table, formulate any concerns, comments, or questions you 
have with regard to the content of the paper. 
8. Send in the completed evidence table  
- The evidence table and GRADE Profiles are the basis to write a summary of evidence and 
recommendations. 
- You can continue with writing the summary of evidence and draft recommendations.  
- We will check and if needed complete the evidence table. Please remember that each paper in 
the evidence table should be mentioned in the summary of evidence or excluded with an 




Ⓘ FRAMEWORK FOR RECOMMENDATIONS 
The justification should comprise the following considerations:  
 








s Are the desirable 
effects large relative to 
the undesirable 
effects? 
☐ Benefits outweigh harms/burden 
☐ Benefits slightly outweigh harms/burden 
☐ Benefits and harms/burden are balanced  
☐ Harms/burden slightly outweigh benefits 
☐ Harms/burden outweigh benefits 





What is the overall 




☐ Very low 
☐ No included studies  




What are the patient 
values and what 
certainty do we have 
about them?  
 ☐ Little uncertainty and similar values 
 ☐ Some uncertainty or some variation 






s Is the incremental cost 
(or resource use) small 
relative to the 
benefits? 
☐ Cost is very small relative to the benefits 
☐ Cost is small relative to the benefits 
☐ Cost is borderline relative to the benefits 
☐ Cost is high relative to the benefits 













What would the 
impact be on health 
equity? 
☐ Reduced  
☐ Probably reduced 
☐ Probably no impact 
☐ Probably increased 
☐ Increased 
☐ Varies 
☐ Don’t know 
  
Is the intervention 
acceptable to key 
stakeholders? 
☐ No 
☐ Probably No 
☐ Probably yes 
☐ Yes 
☐ Varies 
☐ Don’t know 
  
Is the intervention 
feasible to implement? 
☐ No 
☐ Probably No 
☐ Probably yes 
☐ Yes 
☐ Varies 







   
Implementation 
considerations13 
   
Research priorities14    
                                                                
12 Are the recommendations applicable to subgroups, and is this mentioned in the recommendation? 
13 Are there any barriers that could restrict the implementation of this recommendation? If so, how can we handle this? 
14 Is there a need for further research on the topic, and is it a priority? If yes, please provide details on how new studies should 
ideally be performed (RCT, large multicenter) and what their focus should be (subgroup of patients, specific intervention). All 
recommendations for research will be added as an annex to the guideline. 
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Ⓙ REVIEWER COMMENTS FORM 
 
 
Contact information of the reviewer 
Name: ……………………………………………………………………………………… 
Country: ……………………………………………………………………………………… 
E-mail address: ……………………………………………………………………………………… 
Organization15: ……………………………………………………………………………………… 
Statement of Confidentiality. 
 
As a reviewer of this ESHRE document you have been or may be exposed to certain confidential and/or 
proprietary information, materials or data. It is important to the integrity of the writing process and final work 
that this information should be kept strictly confidential and not disclosed at any time under any 
circumstance. 
I will not disclose any confidential and/or proprietary information, materials or data related to Working 
Group’s work to any third party, but keep this information strictly confidential. 
I will keep any confidential and/or proprietary information, materials or data in my possession in a safe 
and secure place to protect against inadvertent disclosure.  
I will not use any confidential information and/or proprietary information, materials or data for any purpose 
other than participating in the review procedure. 
 
 
Signature (or state your 
name): 
……………………………………………………………………………………… 
Date:  ………………………………………………………………………………………  
  
                                                                
15 if you are responding as an individual, please leave blank 
Guideline: …………………………………………. 
Review period: …………………………………………. 
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Comments to the document: 
 
Page Line Comment 
   
   
   
   
   
   
   
   
   
   
   
   
   
(Add more lines if you need to) 
 
Please send completed forms (as word-document or pdf) to guidelines@eshre.eu before XX. 
All comments will be revised by the working group and assessed. If the comment is accepted by the working group, 
it will result in a modification of the document. If not, the working group will formulate a reply to the reviewer. The 
details of the review procedure, the comments, modifications and replies will be summarized in a review report 
which will be available online.  





Ⓚ   DOCUMENT ASSESSMENT TOOL FOR  
UPDATING GUIDELINES 
 
Adapted from [28] 
 
Number and title of guideline   
Current Report Date  
Last Literature Search Date  
Date Assessed   
Research specialist  
Outcome (for internal use)  
Assessment:  
For each document, please respond YES or NO to all the questions below.  Provide an explanation of each answer as necessary. 
1. Is the document still relevant (clinically or to the care system as a whole in some 
way)? 
 
2. Should full assessment and review of this document be deferred until next year? 
Consider YES if:    
 The document is less than three years old, and there is no reason to doubt the 
recommendations   
 The document is between three and five years old, and a justification can be 
provided as to why the recommendations can be considered trustworthy for 
another year 
 
3. Do the questions and search criteria as they are in the document address current 
needs,  such that an updated literature search would be useful and identify 
relevant evidence?  
Consider NO if:  
  The standard of care has shifted significantly since the last version of the 
document, such that the questions only address the topic in part 
 There are new, significant options (for treatment, diagnosis, etc.) available 
that are not covered by the current questions, such that new questions would 
need to be added to the document  
 In general, if you believe that for the document to still be useful it will have to 
substantially be rewritten 




4. Does the document have an impact on access to care (that is, are decisions about 
access or payment for care made by the Ministry, CCO, or other organizations 
based on the recommendations in this document)? 
Consider YES if:    
 Ministry funding decisions have been, are, or will be made on the basis of this 
document   
 An indication for a chemotherapy regimen was funded, or rejected, based on 
the document 
 Case by case review or out of country requests are known to be decided 
based on the document  
 Funding for some screening, diagnostic, staging or treatment procedure was 
or is determined 
 
5. Is there known evidence that has been published since this document’s last 




6. Should this document be taken off the website while it awaits full review, or can it 
be left there with an “IN REVIEW” watermark?  
Consider YES if:    
 If followed, even in error, the recommendations have the potential to cause 
harm to patients. 
 




 ○ ENDORSE 
The recommendations are still current and relevant for decision making. This 
can happen when there is a very strong justification to conclude that without 
a search for new evidence, the recommendations are still valid16. 
○ DEFER The document remains current and credible enough to wait until the next 
assessment. 
○ REVIEW The document will undergo a review for currency and relevance. 
○ ARCHIVE The document cannot be endorsed or deferred, and the recommendations 





                                                                
16 For example, in cases in which added evidence will not change the recommendations because the existing evidence is so 
definitive, of high quality, and adequate quantity or in cases in which no additional evidence in that topic will be forthcoming 
because it is no longer an area of inquiry. 
17 This may happen because the recommendations are no longer clinically relevant and applicable to current practice. Or, it 
may be because the developing group has little or no interest in maintaining them; for example, the topic areas may have 
changed so much that developing a new document is a more practical option than updating the existing one. Archived 
documents may still be useful for academic or other information purposes 
